Winlevi

USDailyMed:Clascoterone AU:D D10AX06(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-only [(8R,9S,10R,13S,14S,17R)-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate 19608-29-8 11750009 DB12499 9924713 XN7MM8XG2M D11451 ChEMBL3590187 DTXSID10471883 Interactive image CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)CO InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h13,17-19,25H,4-12,14H2,1-3H3/t17-,18+,19+,22+,23+,24+/m1/s1Key:GPNHMOZDMYNCPO-PDUMRIMRSA-N Clascoterone, sold under the brand nameWinlevi, is anantiandrogenmedication which is usedtopicallyin the treatment ofacne.The medication is used as acreambyapplication to the skin, for instance thefaceandscalp.Clascoterone is an antiandrogen, orantagonistof theandrogen receptor(AR), thebiological targetofandrogenssuch astestosteroneanddihydrotestosterone.It shows minimalsystemicabsorptionwhen applied toskin. Clascoterone was developed by Cassiopea and was approved for medical use in the United States in August 2020 and in the European Union in October 2025.The USFood and Drug Administration(FDA) considers it to be afirst-in-class medication.